Course Outline and Syllabus for Students
|
|
- Cory Long
- 6 years ago
- Views:
Transcription
1 Course Outline and Syllabus for Students Name: Daniela Gallo-Hershberg & Carlo DeAngelis Course Number: PHM 301H1 Course Title: Oncology, Hematology & Immunology Pharmacotherapy Course Description: This course is designed to provide pharmacy students with the knowledge in pathobiology, pharmacology, pharmacotherapy, clinical pharmacokinetics required to be a practitioner in oncology, haematology & immunology therapeutics. The course will be taught using a variety of techniques including on-line lectures, case-based learning and small interactive group learning. Required: Yes Elective: No 1. Course Learning Objectives: Upon completion of this course, students will have achieved the following level of learning objectives: Introductory = knowledge and comprehension of concepts, definitions, Intermediate = application of concepts to simple situations Advanced = application of concepts to more complex situations with ability to synthesize and evaluate Oncology Knowledge 1. Describe the pathophysiology of cancer including the hallmarks of cancer, the metastatic process, tumour biology, tumour markers, and mechanisms of resistance. [INTERMEDIATE] 2. Discuss the epidemiology of cancer including various causative factors (environmental versus non-environmental) 3. Evaluate the role and appropriateness of various screening methods (self-examination, clinical examination, mammography, Fecal Occult Blood Test, colonoscopy, sigmoidoscopy biological markers, CT scan, MRI, etc., ) for people of varying risks of developing various cancers (e.g. breast, colon, cervical, prostate) including the benefits/risks, limitations, age groups affected, frequency of screening and cost. [INTERMEDIATE] 4. Identify the main treatment modalities of cancer (surgery, radiation and systemic therapy) including their role and use at various stages of the disease process. 5. Categorize the different intents of treatment with chemotherapy and radiation, including neoadjuvant, adjuvant and palliative treatment. [INTERMEDIATE] 6. Compare and contrast the antineoplastic agents utilized in the treatment of various cancers, based on the following criteria: mechanism of action, mechanism of resistance, pharmacokinetics, pharmacodynamics, pharmacogenomics, adverse effects, contraindications, drug interactions,(drug-drug, drug-food, drug-laboratory), convenience, cost, onset of action, formulations, stability and sterility. [INTERMEDIATE] 7. Explain the rationale for combination chemotherapy to treat various types of cancer. [INTERMEDIATE] 8. Explain the mechanism of action, place in therapy and role in conjunction with chemotherapy. of targeted therapies (e.g., vascular endothelial growth factor inhibitors, epithelial growth factor receptor inhibitors,), [INTERMEDIATE] 9. Discuss for the following chemotherapy-induced non-hematological adverse effects (nausea/vomiting, mucositis), the pathophysiology, epidemiology, clinical presentation, consequences, risk factors and natural history. [INTERMEDIATE
2 10. Describe the mechanism of various adverse effects related to biologic/targeted therapies (e.g., vascular endothelial growth factor inhibitors, epithelial growth factor inhibitors, monoclonal antibodies), including epidemiology, clinical presentation, consequences (clinical impact) risk factors, as well as non-pharmacological & pharmacological management. [INTERMEDIATE] 11. Compare and contrast the relevant available classes of antiemetics used for the treatment of chemotherapy-induced nausea and vomiting based on the following criteria: indication, mechanism of action, efficacy, pharmacokinetics, pharmacodynamics, pharmacogenomics, adverse effects, contraindications, drug interactions,(drug-drug, drug-food, drug-laboratory), convenience, cost, onset of action, formulations, stability and sterility. [INTERMEDIATE] 12. Compare and contrast the relevant available pharmacological and non-pharmacological treatment options used for the prevention and treatment of chemotherapy and radiation-induced mucositis based on the following criteria: indication, mechanism of action, efficacy, pharmacokinetics, pharmacodynamics, pharmacogenomics, adverse effects, contraindications, drug interactions,(drug-drug, drug-food, drug-laboratory), convenience, cost, onset of action, formulations, stability and sterility. [INTERMEDIATE 13. Develop prevention and management strategies for common non-hematological adverse effects of systemic anticancer treatment 14. Discuss the pathophysiology, epidemiology, clinical presentation, consequences, risk factors and natural history for pain related to cancer. [INTERMEDIATE] 15. Compare and contrast the relevant available classes of analgesics used for the treatment of pain related to cancer based on the following criteria: indication, mechanism of action, efficacy, pharmacokinetics, pharmacodynamics, pharmacogenomics, adverse effects, contraindications, drug interactions,(drug-drug, drug-food, drug-laboratory), convenience, cost, onset of action, formulations, stability and sterility. [INTERMEDIATE] 16. Develop a therapeutic plan for the management of cancer induced pain
3 Hematology Knowledge 1. Explain the normal process of hematopoiesis including the formation of red and white blood cells and platelets 2. Identify various disorders of abnormal hematopoiesis including Thalassemia, Sickle Cell disease, Hemochromatosis, Thrombocytopenia, Aplastic Anemia 3. Discuss for the following chemotherapy-induced haematological adverse effects (anemia, neutropenia), the pathophysiology, epidemiology, clinical presentation, consequences, risk factors and natural history. [INTERMEDIATE] 4. Compare and contrast the relevant available classes of granulocyte colony-stimulating factors (filgrastim, pegfilgrastim) used for the treatment of chemotherapy-induced neutropenia, based on the following criteria: indication, mechanism of action, efficacy, pharmacokinetics, pharmacodynamics, pharmacogenomics, adverse effects, contraindications, drug interactions,(drug-drug, drug-food, drug-laboratory), convenience, cost, onset of action, formulations, stability and sterility. [INTERMEDIATE] 5. Compare and contrast the relevant available classes of erythropoiesis stimulating agents (epoetin-alfa, darbepoetin) used for the treatment of chemotherapy-induced anemia, based on the following criteria: indication, mechanism of action, efficacy, pharmacokinetics, pharmacodynamics, pharmacogenomics, adverse effects, contraindications, drug interactions,(drug-drug, drug-food, drug-laboratory), convenience, cost, onset of action, formulations, stability and sterility. [INTERMEDIATE] 6. Develop a therapeutic plan for the prevention and management of neutropenia and anemia associated with anticancer treatment [INTERMEDIATE] 7. Discuss the pathophysiology, epidemiology, clinical presentation, consequences, risk factors, natural history and management of common haematological malignancies (e.g. lymphoma, leukemia, multiple myeloma). [INTERMEDIATE]. Immunology - Knowledge 1. Discuss the pathophysiology, epidemiology, clinical presentation, risk factors, drugs that may cause/exacerbate, natural history, diagnosis and differential diagnosis for the following conditions: inflammatory bowel disease and rheumatoid arthritis. [INTERMEDIATE] 2. Identify the appropriate (laboratory, clinical biochemistry, pathology, histology, medical imaging) findings use in the diagnosis and on-going monitoring of inflammatory bowel disease and rheumatoid arthritis. [INTERMEDIATE] 3. Explain the importance of the immune system in solid organ transplantation. [INTERMEDIATE] 4. Compare and contrast the relevant pharmacological and nonpharmacological treatment options used for the treatment of inflammatory bowel disease, including 5-ASA, corticosteroids, immunosuppressants, antibiotics, and tumour necrosis factor antagonists, based on the following criteria: indications, mechanism of action, pharmacokinetics, pharmacodynamics, adverse effects, contraindications, drug interactions (drug-drug, drug-food, drug-laboratory), convenience, cost, onset of action, formulations, stability, and with special attention to geriatrics. [INTERMEDIATE] 5. Compare and contrast the relevant pharmacological treatment options for rheumatoid arthritis including the place in therapy of non-steroidal anti-inflammatory agents, DMARDs and tumour necrosis factor antagonists, based on the following criteria: indications, mechanism of action, pharmacokinetics, pharmacodynamics, adverse effects, contraindications, drug interactions (drug-drug, drug-food, drug-laboratory), convenience, cost, onset of action, formulations, stability, and with special attention to geriatrics. [INTERMEDIATE] 6. Compare and contrast the relevant pharmacological treatment options used to prevent rejection in solid organ transplantation, based on the following criteria: indications, mechanism of action, pharmacokinetics, pharmacodynamics, adverse effects, contraindications, drug interactions (drug-drug, drug-food, drug-laboratory), convenience, cost, onset of action, formulations, stability and sterility. [INTERMEDIATE] 7. Describe the non-pharmacologic management for the selected conditions. [INTERMEDIATE]
4 Skills 1. Select relevant data from: review of systems, laboratory tests, medical imaging to assess drug therapy needs. [INTERMEDIATE] 2. Apply relevant findings from review of systems, laboratory tests and medical imaging to determine actual and potential drug therapy needs. [INTERMEDIATE] 3. Analyze relevant information from subjective and objective sources (ROS, medical imaging, diagnostic test, biochemical markers) to determine drug therapy problems, urgency, and priority for a given clinical situation. [INTRODUCTORY] 4. Demonstrate the ability to critique and interpret results from observational studies, randomized controlled trials and meta-analyses in hematology/oncology/immunology. [INTRODUCTORY] 5. Interpret various prognostic factors related to cancer and their impact on treatment approaches. [INTERMEDIATE] 6. Justify the selection of a preferred antiemetic regimen for a selected chemotherapy regimen based on assessment of its emetogenic potential. [INTERMEDIATE] 7. Assess the use of granulocyte colony-stimulating factors (filgrastim, pegfilgrastim) for patients receiving selected chemotherapy regimens, based on patient risk factors, disease-related factors and treatment-related factors, in the prophylactic and treatment settings. [INTERMEDIATE] 8. Assess the use of erythropoiesis stimulating agents (epoetin-alfa, darbepoetin) for patients receiving selected chemotherapy regimens, based on patient risk factors, disease-related factors and treatment-related factors in the prophylactic and treatment settings. [INTERMEDIATE] 9. Develop and justify a care plan with follow up for a given clinical situation. [INTERMEDIATE] 10. Evaluate the quality, accuracy, and completeness of the care plan. [INTERMEDIATE] Attitudes/Values 1. The student will undertake assessment and care plan development activities in a manner respecting patient autonomy and the individual therapeutic goals. [INTERMEDIATE] 2. The student will use interprofessional patient centered care principles to reach decisions for therapeutic alternatives. [INTERMEDIATE] 3. The student will demonstrate respect and collaboration in team functioning. [INTERMEDIATE] 2. Rationale for Inclusion in the Curriculum: According to Health Canada cancer is the number one killer of Canadians and it is projected that as the population ages and advances in therapy are made more patients will be living with the disease in the coming years. Traditional cancer therapies have been delivered in the hospital setting because of the need for intravenous administration. However, increasingly new therapies for cancer will be orally administered. Because of cancer prevalence and changing therapeutic strategies aimed at making cancer a chronic disease, pharmacists will be called upon more often to become involved in the care of patients with cancer. It is essential that the graduating pharmacists of the future have a sound foundation in cancer pathophysiology and management. Not only is a greater understanding of the immunological basis of cancer leading to new therapies; but immunological based therapies are increasingly seen as the backbone of disease management for irritable bowel disease (IBD) and rheumatoid arthritis (RA). An understanding of the use of biological agents in cancer complements and will aid pharmacy students in their support of patients with IBD and RA. Hematology is the study of cellular blood components (red and white blood cells and platelets) and, coagulation. An understanding of various disease states and drugs affecting the cellular components of blood is essential to daily pharmacy practice. The key components of the body s immune response are white blood cells and their function. While the immune response is essential in preventing and combating various diseases; its disregulation can result
5 in diseases such as IBD and RA. Modifying the immune response has become the mainstay of therapy for these conditions. Another therapeutic area where regulation of the immune response is critical is the prevention of rejection following transplantation (solid organ and allogeneic bone marrow/stem cell). Finally, there is a growing body of literature linking cancer and the immune system. New therapies are being developed to modulate the immune system which cross the traditional therapeutic boundaries of oncology, haematology, rheumatology, gastroenterology, etc. We have developed this course to help students understand the commonality which exists across traditional therapeutic areas so that knowledge in one area can be applied in another. While the primary focus of the lectures are oncology related many of the principles learned can be applied to the other areas of haematology and immunology. In selecting topics for the course we also did not want to duplicate content from previous courses (e.g. anaemia management). We also feel that the relative weight given to the various therapeutic areas is also reflective of the likelihood a practicing pharmacist is to encounter these patients in day to day practice. 3. Pre-requisites: PHM 145/PSL 205/PHM 143 Anatomy, Physiology and Pathobiology/Pathology related to oncology, haematology and immunology PHM 140 Molecular pharmacology (including basis of gene therapy) PHM 142/144 Metabologic Biochemisty & Immunology PHM Pharmacokinetics (particularly cyclosporine & irinotecan) PHM Pharmaceutics IPE requirements Roles/knowledge of other health care professionals PHM 112 & 212 Pharmacy Informatics & Clinical Trials, Pharmacoepidemiology & Pharmacy Practice Research PHM 105 (MTM-1), PHM 205 (MTM-2), PHM 206 (MTM-3) PHM 101 (General Medicine 1), PHM 201 (Dermatology/EENT), PHM 202 (Endocrinology/Nephrology/Urology), PHM 203 (Infectious Diseases), PHM 204 (Cardiovascular Diseases) 4. Statement of agreement from course coordinators of courses for which this course is a pre-requisite: 5. Co-requisites: (for the current and subsequent year) PHM 305 (MTM-4) PHM Toxicology PHM 302 (Neuropsychiatry) 6. Statement of agreement from coordinators of courses for which this course is a co-requisite: 7. Course Contact Hours and Teaching Methodologies: Didactic (lecture) Large group problem-based or case-based learning Large Group Size Small group problem-based or case-based learning Experiential On-line Other (please specify)* * Other specific information: Total course contact hours 25 hours 14 hours 60 persons hours hours hours 39 hours
6 8. Estimate and description of student's weekly out-of-class preparation time excluding exam preparation: Review on-line lecture (captured as part of course hours) Review learning objectives + prepared materials by classmates (3 7 hrs/ week), higher during weeks of case discussions 9. Course Coordinator and contact information: Carlo De Angelis and another individual to be determined 10. Course Instructors and contact information: 11. Required Resources/Textbooks/Readings: Pharmacotherapy: A Pathophysiologic Approach, seventh edition, J DiPiro, et al. Selected readings from Journal articles and other resources as deemed necessary 12. Recommended Resources/Textbooks/Readings: 13. Topic Outline/Schedule: For each, indicate level of knowledge, skills and attitudes learning objectives Week Content Method Time allotment 1 Course overiew/expections/delivery Online CAPHO Oncology Basics Module 2 Pharmacology of chemotherapy & targeted therapies Summary In Class Case Discussion re: Oncology Basics (breast cancer) Basic Principles Online module Interactive Case 4 x 60 students 3 Pharmacogenomics Wrap Case CRC with incorporating geriatrics taking pt through initial diagnosis, adjuvant therapy, multiple lines of therapy with advanced disease (critical appraisal)? 4 Pathophysiology GI tract i.e. N/V, mucositis secondary to chemo Interactive Case 4 x 60 students Pharmacology of Antiemetics Pharmaceutics Novel Dosage Forms 5 Pharmacokinetics & Therapeutic Drug Monitoring
7 GI + Care Plans -CINV, Mucositis, Diarrhea 6 Pathophysiology + Pharmacotherapy of Adverse Effects of Targeted Therapties Adverse Effects of Targeted Agents + Care Plans 7 Pathophysiology Symptom Management in Advanced Cancer Symptoms Management in Palliative Care - Assessment 8 Pathophysiology of Bone Marrow Disorders Pharmacology ESAs + GCSF Hematological Toxicities - 9 Pathophysiology - Hematological Malignancies Pharmaceutics Novel Dosage Forms (Pediatrics) Maintenance Therapy + Monitoring Pediatrics, Pharmacogenomics 10 Pathophysiology - Dysregulation of the Immune System Infusion-related reactions Pathophysiology Intro to Transplant 11 Pharmacology of anti-rejection agents Pharmacokinetics/TDM Transplant Solid Organ with cases clickers /?twitter feed 30 min 30 min
8 12 Pharmacology Immunosuppressants + DMARDS RA 13 Pharmacology IBD local to systemic treatments IBD Assessment with clicker technology/twitter feed Weekly learning objectives: Sample Learning Objectives for Pharmacotherapy of Nausea/Vomiting 1. Identify the phases and corresponding mechanisms behind chemotherapy-induced nausea and vomiting. 2. Describe the risk factors for prediciting nausea/vomiting chemotherapy-induced nausea/vomtiting 3. Compare and contrast the Hesketh & MASCC classifications systems for identifying the emetogenicity for various chemotherapeutic regimens. 4. Discuss the non-pharmacological strategies to prevent nausea/vomiting. 5. Compare and contrast the MOA, indication, dosing, safety parameters, drug interactions, monitoring parameters, convenience and cost (where possible) for the following agents. 5HT3RAs, NK1-antagonists, corticosteroids, dopamine antagonists, antipsychotics, cannabinoids, benzodiazepines, dimenhydrinate 6. State and justify anti-emetic regimens for high, moderate, low and minimal emetogenic chemotherapy regimens using the ASCO, MASCC and NCCN guidelines. 14. Assessment Methodologies Used: Formative assessment On-line self assessment multiple choice questions Handheld audience response meters Learning Objectives Addressed Assessment 1: various depending on topics covered Assessment 2: various depending on topics covered Assessment 3: values/attitudes learning objectives Assessment 4:
9 Assessment Method Used Assessment 1: Midterm #1 - Multiple choice questions, short written answers Assessment 2: Final exam Multiple choice questions, short written answers Assessment 3: Participation participation in 6 group discussion activities Assessment 4: When Administered Assessment 1: Week 7 Assessment 2: Final Exam period Assessment 3: Group Discussions Assessment 4: Percentage of Course Grade Assessment 1: 45% Assessment 2: 45% Assessment 3: 10% Assessment 4: Remediation Opportunities? None Expectation for pass grades for all Pharmacy courses is 60%. 15. Policy and procedure regarding make-up assignments/examinations/laboratories: Missed Exam/Test Policy Students who miss an examination or a test and who have a valid petition filed with the Registrar s office will be eligible to complete a make-up examination or test. The format of this examination or test will be at the discretion of the course coordinator, and may include, for example, an oral examination. Missed Tutorial/Small group session Policy: Students who miss a scheduled tutorial/small group session and who have a valid petition filed with the Registrar s office will be eligible to: a. Attend a subsequent regularly scheduled small group session/tutorial (if space is available) b. Complete assignment *Note: this applies only for laboratories or tutorials where summative assessment occurs Missed Assignment Policy: Students who fail to submit an assignment by the specified due date, and who have a valid petition filed with the Registrar s office will be eligible to submit the completed assignment, or an alternative assignment based on course requirements, with no academic penalty. Late Assignment Policy: Students who fail to submit an assignment by the specified due date will receive a deduction of 10% % for each day beyond the due date (including/excluding weekends/holidays), to a maximum of 50 %. Assignments will not be accepted for grading after 5 late days. 16. Policy and procedure regarding supplemental assignments/examinations/laboratories:
1. Discuss the Mental Health and Addiction System in Canada and identify the strengths and limitations of such systems.
Course Outline and Syllabus for Students Mental Health and Addiction Elective Course Outline Coordinator Names: Jamie Kellar and Maria Zhang Course Number: PHM386 Course Title: Mental Health and Addictions
More informationCourse Outline and Syllabus for Students
Course Outline and Syllabus for Students Name: Marisa Battistella + Henry Halapy Outline Development: Philip Lui Course Number: PHM 202H1 Course Title: PCT 3 (Endocrinology / Nephrology / Urology) Course
More information1. Discuss the Mental Health and Addiction System in Canada and identify the strengths and limitations of such systems.
Course Outline and Syllabus for Students Names: Jamie Kellar, Beth Sproule Course Number: PHM386 Course Title: Mental Health and Addictions Elective Course Description: This course is designed to provide
More informationCourse Outline and Syllabus for Students
Course Outline and Syllabus for Students Name: Marisa Battistella + Henry Halapy Outline Development: Philip Lui Course Number: PHM 202H1 Course Title: PCT 3 (Endocrinology / Nephrology / Urology) Course
More informationLeslie Dan Faculty of Pharmacy University of Toronto. Course Outline and Syllabus ( )
Leslie Dan Faculty of Pharmacy University of Toronto Course Outline and Syllabus (2017 2018) Course Instructor: Dr. Reina Course Number: PHM143H1 Course Title: Pathobiology and Pathology Course Description:
More informationLeslie Dan Faculty of Pharmacy University of Toronto. Course Outline and Syllabus ( )
Leslie Dan Faculty of Pharmacy University of Toronto Course Outline and Syllabus (2015 2016) Name: Dr. Reina Bendayan Course Number: PHM143H1 Course Title: Pathobiology and Pathology Course Description:
More informationLeslie Dan Faculty of Pharmacy University of Toronto. Course Outline and Syllabus ( )
Leslie Dan Faculty of Pharmacy University of Toronto Course Outline and Syllabus (2012 2013) Name: Professor Reina Bendayan Course Number: PHM143H1 Course Title: Pathobiology and Pathology Course Description:
More informationVersion: PHM352 O Updated: Dec
Course Outline and Syllabus Course Developers: Lawrence Jackson and Lalitha Raman-Wilms Course Coordinator: Lalitha Raman-Wilms Course Number: PHM 352H1: Pharmacotherapy Selective Course Course Title:
More informationCurriculum: Goals and Objectives Department of Medicine Harbor-UCLA Medical Center
MEDICAL ONCOLOGY AND HEMATOLOGY (R2, R3) A. The PURPOSE of this rotation is to afford medical residents a broad clinical and training experience in the clinical diagnosis and management of common adult
More informationPHARMACY PRACTICE (PHM PRAC)
Pharmacy Practice (PHM PRAC) 1 PHARMACY PRACTICE (PHM PRAC) PHM PRAC 305 CONSUMER SELF-CARE AND OVER-THE-COUNTER DRUGS Provides learners with information regarding self-care of common, minor health conditions.
More informationCAPhO Oncology Fundamentals Day Saturday, October 1, 2016
The Canadian Association of Pharmacy in Oncology Presents CAPhO Oncology Fundamentals Day www.capho.org #OFD16 www.acpho.org [Type here] Accreditation CAPhO Oncology Fundamentals Day is accredited by the
More informationEvaluating Exam Review Book and Guide
Pharmacy Prep Evaluating Exam Review Book and Guide Misbah Biabani, Ph.D Director Toronto Institute of Pharmaceutical Sciences (TIPS) Inc. Toronto, ON M2N 6K7 Pharmacy Prep Professional Exams Preparation
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationPGY-2 ONCOLOGY RESIDENCY ROTATION DESCRIPTION
PGY-2 ONCOLOGY RESIDENCY ROTATION DESCRIPTION ROTATION TITLE Outpatient Adult Oncology PURPOSE The outpatient oncology service will provide the PGY-2 resident with the opportunity to further develop and
More informationEducation and Training Strategy
ECN Pharmacy Group Education and Training Strategy Name of person presenting document: Reason for document development: Names of development team: Specify groups of staff to whom the document relates:
More informationLahey Clinic Internal Medicine Residency Program: Curriculum for Hematology
Lahey Clinic Internal Medicine Residency Program: Curriculum for Hematology Faculty representative: Neil Weiner, MD Resident representative: Guiherme Rabinowits, MD Revision date: February 28, 2006 Goals
More information2008 Oncology Pharmacy Preparatory Review Course Learning Objectives
2008 Oncology Pharmacy Preparatory Review Course Learning Objectives Session 1 Symptom Management, Part I, II & III Teresa A. Mays, Pharm D., BCOP Director, Investigational Drug Department San Antonio,
More informationReference No: SG 23/13
Title: Author(s) Ownership: Approval by: Guidelines for the use of granulocyte colony stimulating factor (GSCF) in adult oncology & malignant haematology patients Paula Scullin, Consultant Medical Oncologist,
More informationThe University of Jordan Faculty: Pharmacy Department: Biopharmaceutics and Clinical Pharmacy
The University of Jordan Faculty: Pharmacy Department: Biopharmaceutics and Clinical Pharmacy Program: Pharm.D Academic Year/ Semester 2013-2014 Internal medicine clerkship-oncology supportive care (123601)
More informationUpdate on Chemotherapy- Induced Anemia and Neutropenia Therapies
Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapyinduced
More informationHMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP
More informationBY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,
More informationDRUGS FOR NEOPLASIA. Chapter 37
DRUGS FOR NEOPLASIA Chapter 37 Keywords- You tell Me! Cancer dz characterized by abnormal, uncontrolled cell division Tumor swelling, abnormal enlargement or mass of tissue Carcinogen any substance or
More informationGuideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology
(G-CSF) for Adults in Oncology and Haematology For Use in: By: Oncology and Haematology Inpatients and Outpatients Oncologists and Haematologists For: Division responsible for document: Key words: Name
More informationThe University of Jordan. Accreditation & Quality Assurance Center. COURSE Syllabus
The University of Jordan Accreditation & Quality Assurance Center COURSE Syllabus 1 Course title Pharmacology 2 2 Course number 1203364 Credit hours (theory, practical) 3 hours/theory 3 Contact hours (theory,
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 6 Last Review Date: September 15, 2017 Granix Description Granix (tbo-filgrastim)
More information2018 OCN Keywords January 22, 2018 Subject Area Weight Keywords
Subject Area Weight Keywords Care Continuum 19% Care Continuum Coordination of Care Navigation Psychosocial Symptom Management Health Promotion/Screening and Early Detection Disease Prevention High-Risk
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More information2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives
2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives Acute Leukemia/Tumor Lysis Syndrome John M. Valgus, Pharm.D., BCOP Hematology/Oncology Specialist University of North
More informationNab-Paclitaxel (Abraxane) and Gemcitabine For Pancreatic Adenocarcinoma Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent & Rate 1 8 15 Sodium Chloride 0.9% 100ml Infusion Fast Running Dexamethasone 8mg Oral Ondansetron 8mg Oral/ IV Chlorphenamine 10mg Intravenous Slow
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Section: Prescription Drugs Effective Date: April 1, 2014 Subject: Granix 1 of 7 Last Review Date:
More information2 Diagnosis and Staging of Cancer 2.1 Pathophysiology of cancer 2.2 Classification and staging 2.3 Diagnostic measures for specific cancer types
Oncology Nursing Sub-Specialty Module Reference: Gobel B. M., Triest-Robertson S. & Vogel W.H. (Eds). (205). Advanced Oncology Nursing Certificate Review and Resources Manual. Pittsburgh: Oncology Nursing
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Subject: Granix 1 of 7 Last Review Date: September 18, 2015 Granix Description Granix (tbo-filgrastim)
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationStem cell transplantation. Dr Mohammed Karodia NHLS & UP
Stem cell transplantation Dr Mohammed Karodia NHLS & UP The use of haemopoeitic stem cells from a donor harvested from peripheral blood or bone marrow, to repopulate recipient bone marrow. Allogeneic From
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInvestigating Plinabulin for Prevention of Chemotherapy-Induced Neutropenia
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/project-oncology/origins-and-impacts-severe-neutropenia-newpharmacotherapy/9650/
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 7 Last Review Date: December 2, 2016 Granix Description Granix (tbo-filgrastim)
More informationACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology
ACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology ACGME approved: June 27, 2006; effective: July 1, 2007 ACGME approved focused revision: September 30, 2012; effective:
More informationSupportive Care for Patients with Cancer
3:15pm - 4:15pm: Breakout 4 - Oncology Option A: Supportive Care for Patients with Cancer ACPE UAN 0107-0000-10-021-L01-P 0.1 CEU/1.0 Hr. Activity Type: Application-Based Program Objectives for Pharmacists:
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationESMO HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE
ESMO 2016 - HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE FLORIAN SCOTTE Cancer Department Supportive Care in Cancer Unit Georges Pompidou European Hospital Paris France esmo.org DISCLOSURE SLIDE Consultant
More informationCompetent Pain Management for Older Patients With Cancer
Session length: 2 hours, 53 minutes Contact hours: 3.5 Pharmacology hours offered: 30 minutes 2005 ONS Virtual Institutes of Learning Evaluation Form Competent Pain Management for Older Patients With Cancer
More information12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization
Table of Contents: PART I: Molecular and Cellular Basis of Hematology 1 Anatomy and Pathophysiology of the Gene 2 Genomic Approaches to Hematology 3 Regulation of Gene Expression, Transcription, Splicing,
More informationMEASURE SPECIFICATIONS
QOPI REPTING REGISTRY (QCDR) 2018 QOPI 5 QOPI 11 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Combination chemotherapy
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationMEASURE SPECIFICATIONS
QOPI REPTING REGISTRY (QCDR) 2018 QOPI5 Title Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Description Percentage
More informationQUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS
QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors
More informationImplementation of Hematology- Oncology Education Program. Amir Steinberg, MD Samuel Oschin Comprehensive Cancer Center Cedars-Sinai Medical Center
Implementation of Hematology- Oncology Education Program Amir Steinberg, MD Samuel Oschin Comprehensive Cancer Center Cedars-Sinai Medical Center Cedars-Sinai Medical Center Large, tertiary care center
More informationRotation Description: R3 Hematology-Oncology Rotation
Rotation Description: R3 Hematology-Oncology Rotation I. General Information A. Rotation Length: 4 weeks B. Faculty: Bradley Lair, M.D. Roy Molina, M.D. Roscoe Morton, M.D. Steve Heddinger, M.D. (rotation
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Antiemetic Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 8 References... 8 Effective Date... 1/1/2018
More informationHEMATOLOGY MODULE STUDY GUIDE Course Title Hematology Module B Course Coordinator: Dr. Irfan Ashraf
HEMATOLOGY MODULE STUDY GUIDE A Course Title Hematology Module B Course Coordinator: Dr. Irfan Ashraf C Course Committee Dr. Irfan Ashraf, Dr. Syeda Zarreen Raza, Dr. Rubia Kashif D Objectives of Study
More informationThis is a controlled document and therefore must not be changed
AZACITIDINE NICE TA218 Treatment of adults not eligible for haematopoietic stem cell transplantation who have: Intermediate-2 and high-risk MDS according to the International Prognostic Scoring System
More informationSTUDY GUIDE. At the end of the module, the students should be able to: Outcomes
Module Title Introduction Hematology STUDY GUIDE This Hematology module hinges on the previous Blood module taught in semester 2. This module will focus on the abnormal aspects of Blood. It will deal with
More informationManagement of common chemotherapy related side effects. Dr Lee-Ann Jones
Management of common chemotherapy related side effects Dr Lee-Ann Jones Deciphering oncology terms treatment intent Chemotherapy terms / intents Adjuvant chemotherapy - Chemotherapy given to destroy residual/
More information9/3/2014. Conflict of Interest Disclosures. Learning Objectives. Definitions of Nausea/Vomiting. Definitions of Nausea/Vomiting
Conflict of Interest Disclosures LeAnn B. Norris Teva Pharmaceuticals Last Chance Webinar 2014 Oncology Supportive Care LeAnn B. Norris, PharmD, BCPS, BCOP Assistant Professor South Carolina College of
More informationStudent Project PRACTICE-BASED RESEARCH
Pharmacist-Driven Management of Chemotherapy Induced Nausea and Vomiting in Hospitalized Adult Oncology Patients. A Retrospective Comparative Study Ramy Elshaboury, PharmD 1 and Kathleen Green, PharmD,
More informationYEREVAN STATE MEDICAL UNIVERSITY DEPARTMENT OF HEMATOLOGY COURSE DESCRIPTION HEMATOLOGY
1. Module/unit Code II. 1.2. 2. Module/unit Title Hematology 3. Subject Field Internal Diseases Group 4. Faculty/Department General Medicine, Department of Hematology 5. Programme(s) to which the Doctor
More informationManaging Older Patients With Lymphoma and Multiple Myeloma
2006 ONS Congress Webcast Evaluation Form Managing Older Patients With Lymphoma and Multiple Myeloma Session length: 1 hour, 45 minutes Contact hours: 1.5 Pharmacology hours offered: 15 minutes How to
More informationShannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008
Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008 Study Title: Observational Study to Determine the Effect of an Emergency Department Adult Oncology Stat Antibiotic Protocol on Clinical Outcomes
More informationAdvances in Chemotherapy for Non-Small Cell Lung Cancer
Advances in Chemotherapy for Non-Small Cell Lung Cancer Evan W. Alley, MD, PhD Clinical Associate Professor Abramson Cancer Center at Penn Presbyterian Lung Cancer: Overview Second most common cancer in
More informationCourse Outline and Syllabus
Course Outline and Syllabus Name: Nohjin Kee, Chris Perumalla Course Number: PSL205H1 Course Title: Basic Human Physiology Course Description: A physiology course for pharmacy students on functions of
More informationNCCN Chemotherapy Order Templates
USER GUIDE NCCN Chemotherapy Order Templates (NCCN Templates ) Access to the NCCN Chemotherapy Order Templates (NCCN Templates ) for non-commercial users is available via subscription. Prior to accessing
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.08 Subject: Leukine Page: 1 of 6 Last Review Date: March 13, 2014 Leukine Description Leukine (sargramostim)
More informationPharmacology I PHAR 400
Pharmacology I PHAR 400 Course Description The basic principles of pharmacology will be taught in this first semester course. There will be three blocks of concentration: basic pharmacology, autonomic
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationChemotherapy Training and Assessment Policy. For Medical Prescribers and Pharmacy Verifiers
Chemotherapy Training and Assessment Policy For Medical Prescribers and Pharmacy Verifiers For approvals and version control see Document Management Record on page 6 Doc Ref: AngCN-CCG-C36 Approved and
More informationSTANDARDIZED PROCEDURE MANAGEMENT OF CHEMOTHERAPY (ADULT, PEDS)
I. Definition Chemotherapy is the use of cytotoxic drugs, hormones, antihormones, and biologic agents to treat malignancies. Selection of specific drugs or protocols is based on results of prior/ongoing
More informationCircle Yes or Y N. [Note: requests without this information will not be accepted.] [If no, then no further questions.
10/01/2016 Prior Authorization Aetna Better Health of West Virginia COLO STIMULATIG FACTORS (WV88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationWhy Patients Experience Nausea and Vomiting and What to Do About It
Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer
More informationUpdates in the Management of Anemia in Cancer. Taylor M. Ortiz, MD May 19, 2017
Updates in the Management of Anemia in Cancer Taylor M. Ortiz, MD May 19, 2017 Objectives Recall common causes of anemia in patients with cancer Understand risks/benefits of blood transfusion in patients
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More information2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationAPPLICANT INFORMATION
Pediatric Hematology Oncology / Stem Cell Transplant Nurse Practitioner Graduate Fellowship Program TEXAS CHILDREN S CANCER AND HEMATOLOGY CENTER S NURSE PRACTITIONER GRADUATE FELLOWSHIP APPLICATION Mail
More informationNinlaro. (ixazomib) New Product Slideshow
Ninlaro (ixazomib) New Product Slideshow Introduction Brand name: Ninlaro Generic name: Ixazomib Pharmacological class: Proteasome inhibitor Strength and Formulation: 2.3mg, 3mg, 4mg; gel caps Manufacturer:
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationMASTER OF SCIENCE IN PHYSICIAN ASSISTANT STUDIES DIDACTIC COURSE SEQUENCE
MASTER OF SCIENCE IN PHYSICIAN ASSISTANT STUDIES DIDACTIC COURSE SEQUENCE Semester 1 - Spring PAS 501 Professional Practice-I: Professional Issues, Health Policy and the PA History and Role in Modern Health
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationCircle Yes or No Y N. (Note: requests without this information will not be accepted.) [If no, then no further questions.]
04/25/2016 Prior Authorization AETA BETTER HEALTH OF LA MEDICAID Colony Stimulating Factors (LA88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationPublic Dissemination Effective: January 2018
Board of Pharmacy Specialties Board Certified Geriatric Pharmacist (BCGP) Detailed Content Outline 1. GENERAL PRINCIPLES OF AGING (20%) A. Apply the knowledge of physiologic changes associated with aging
More informationSystemic management of pancreatic cancer: Supportive care
Systemic management of pancreatic cancer: Supportive care Snežana Bošnjak @bosnjaksupport Institute for Oncology and Radiology of Serbia Serbia, Belgrade Supportive Care in Cancer The prevention & management
More informationSER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017
SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017 Leading the Microbiome Revolution Forward Looking Statements Some of the statements in this presentation
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationInternational Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany. What was hot at MASCC/ISOO Annual Meeting this year?
International Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany What was hot at MASCC/ISOO Annual Meeting this year? Supportive Care Makes Excellent Cancer Care Possible. This slogan
More information2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures
2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures The table below includes measures directly relevant to oncology providers as well as general
More informationLecture 1: Carcinogenesis
Lecture 1: Carcinogenesis Anti-cancer (oncology agents): These are perhaps the most dangerous of drugs, other than the narcotic analgesics. This is due to their toxicities. Killing or inhibiting cancer
More informationBalancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer
2006 ONS Congress Webcast Evaluation Form Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer Session length: 1 hour, 49 minutes Contact hours: 1.6 Pharmacology hours offered:
More informationPEDIATRIC HEMATOLOGY/ONCOLOGY ROTATION
DEPARTMENT OF PEDIATRICS NATIONAL CAPITAL CONSORTIUM PEDIATRIC RESIDENCY PROGRAM PEDIATRIC HEMATOLOGY/ONCOLOGY ROTATION February 2017 1. DURATION OF ROTATION: One (1) block/four (4) weeks. 2. ELIGIBILITY:
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More information2013 Oncology Pharmacy Specialty Recertification Home Study Syllabus Learning Objectives
2013 Oncology Pharmacy Specialty Recertification Home Study Syllabus Learning Objectives Breast Cancer Chad Barnett, Pharm.D., BCOP Clinical Pharmacy Specialist The University of Texas M.D. Anderson Cancer
More informationBEVACIZUMAB (AVASTIN ), CARBOPLATIN & PACLITAXEL for Ovarian Cancer
DRUG ADMINISTRATION Day Drug Dose Route Diluent & Rate Day 1 Sodium Chloride 0.9% 250/500ml Infusion Fast Running Dexamethasone See Below* Chlorphenamine 10mg Intravenous Slow bolus Ranitidine 50mg Intravenous
More informationProtocol Abstract and Schema
Protocol Abstract and Schema Phase II study of Bevacizumab plus Irinotecan (Camptosar ) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas,
More informationUICC EML Review 2014
UICC EML Review 2014 Granulocyte Stimulating Agents (G- CSF) Supplemental Document Many antineoplastic agents are cytotoxic to the bone marrow and prevent the development of granulocytes necessary to fight
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
More informationCisplatin and Gemcitabine (bladder)
Cisplatin and Gemcitabine (bladder) Indication Palliative therapy for locally advanced or metastatic bladder cancer in patients with good renal function. Palliative therapy for urothelial transitional
More informationGUIDELINES FOR THE USE OF G-CSF & PEGFILGRASTIM (NEULASTA)
GUIDELINES FOR THE USE OF G-CSF & PEGFILGRASTIM (NEULASTA) Document Reference: N/A Version: V1.1 Dr Andrew Sykes Document Document June So Owner: Chair Drugs & Author: Director of Pharmacy Therapeutics
More information